Cambridge Healthtech Institute’s 18th Annual

Optimizing Cell Line and Cell Culture Processes

Improving Upstream Productivity and Biologics Quality

August 15-16, 2022

 

The biopharm industry has made great progress in upstream processing in the last decade, resulting in today's mAb production yield of 10g/L or more. Better cell culture media, more stable cell lines, and bioreactor control strategies have helped improve upstream productivity and biologics quality. Going into the next decade, companies are looking to newer technologies and better process design, including omics approaches, process intensification, automation, PAT, and process monitoring to develop higher productivity, higher intensity, integrated, and more robust manufacturing for optimal upstream performance. Join CHI's 18th Annual Optimizing Cell Culture Process and Cell Line Development to hear case studies on these new challenges and novel formats.  

 

Coverage will include, but is not limited to:

 

  • New challenges in cell line development for novel formats - bispecifics, multispecifics, exosomes, nanoparticles, nucleic acids
  • Development of stable cell lines for AAV production - from transient expression to cell line engineering
  • Non-mammalian cell-based expression systems for antibody mimetics and novel scaffolds
  • High throughput methods and automation in cell line development
  • Novel transposase tools for cell line development
  • Emerging technologies and approaches – transposon vector-mediated gene transfer, omics tools (genomics, proteomics, metabolomics)
  • Cell engineering and expansion
  • Assessing cell stability and product quality attributes
  • Cell culture control strategies and analysis - pH, composition of media, feeds
  • Improvements in cell culture media, from serum-containing to protein-free, chemically-defined media
  • Top-Down and Bottom-Up approach in cell culture media process
  • Monitoring and controlling glycosylation
  • Selecting a bioreactor system that best fits your product - fed-batch, perfusion, chemostate process, etc.
  • Scaling up - how can bioprocesses be transferred from lab to production scale without performance loss?
  • Scale-up of transient expression system, mRNA processes
  • Intensified processes and integrated continuous processing with single-use technologies in upstream processes - their impact on speed, productivity, and quality

 

 

The deadline for priority consideration is February 4, 2022.

 

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

 

Opportunities for Participation:

 

 

For more details on the conference, please contact:

Mimi Langley

Senior Conference Director

Cambridge Healthtech Institute

Phone: +1 781-972-5439

Email: mlangley@healthtech.com

 

For sponsorship information, please contact:

 

Companies A-K

Sherry Johnson

Sr. Business Development Manager

Cambridge Healthtech Institute

Phone: +1 781-972-1359

Email: sjohnson@healthtech.com

 

Companies L-Z

Jon Stroup

Sr. Business Development Manager

Cambridge Healthtech Institute

Phone: +1 781-972-5483

Email: jstroup@healthtech.com


Submit a Speaker Proposal